AstraZeneca Plc signed an agreement with Torrent Pharmaceuticals Ltd. to brand and market 18 of the Indian drug maker medicines in 9 emerging economies, marking the
AstraZeneca is expanding in so-called branded generics as it seeks to boost sales in emerging markets to 25 percent of annual revenue by 2014, from 13 percent in 2009. Branded generics is a way to accelerate growth in emerging markets.
AstraZeneca follows
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1735.45 |
Dr. Reddys Lab | 1144.05 |
Cipla | 1441.70 |
Lupin | 2026.50 |
Zydus Lifesciences | 885.70 |
View more.. |